Reports

Sale

Idiopathic Pulmonary Fibrosis Treatment Market

Global Idiopathic Pulmonary Fibrosis Treatment Market Size, Report, Forecast: By Drug Class: Tyrosine Inhibitors, MAPK Inhibitors, Autotaxin Inhibitors, Others; By Marketed Drugs; By Route of Administration; By Drug Type; By Treatment Channel; By End User; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032

Global Idiopathic Pulmonary Fibrosis Treatment Market Outlook

The global idiopathic pulmonary fibrosis treatment market size attained a value of USD 3.59 billion in 2023, driven by growing cases of lung diseases, increasing geriatric population, and rising patient awareness, which is likely to propel the demand for idiopathic pulmonary fibrosis treatment. The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032 to attain a value of USD 5.96 billion by 2032.

 

The industry is expected to attain a value of USD 4.3 billion by 2026. The market is being dominated by the North America and European regions.

 

Global Idiopathic Pulmonary Fibrosis Treatment Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Segmentation

Idiopathic pulmonary fibrosis (IPF) refers to a severe lung disease. As you breathe in, oxygen travels through tiny airbags in your lungs and into your bloodstream. This flows to the organs from there. IPF causes scar tissue to develop within the lungs, making it hard to breathe. The treatment of this disease can help in slowing down the damage to the lungs.

 

Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The idiopathic pulmonary fibrosis treatment market can be broadly categorised based on drug class into:

  • Pirfenidone
  • Nintedanib

The EMR report looks into the regional markets for idiopathic pulmonary fibrosis like North America, Latin America, Europe, the Middle East and Africa, and the Asia Pacific.

 

Global Idiopathic Pulmonary Fibrosis Treatment Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis

The increased prevalence of idiopathic pulmonary fibrosis (IPF) and the increasing geriatric population are the key drivers of the market. The increase in the number of people smoking cigarettes, leading to a high prevalence of IPF, is also projected to fuel the growth of the market.

 

Competitive Landscape

The report presents a detailed analysis of the following key players in the global market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Boehringer Ingelheim International GmbH.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Trevi Therapeutics
  • FibroGen,Inc.
  • TORAY INDUSTRIES, INC.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Asahi Kasei Corporation
  • Galapagos NV
  • ZAMBON COMPANY S.P.A.
  • Novartis AG
  • Neopharm Group
  • Galecto Biotech
  • Kadmon Holding, Inc.
  • Promedior, Inc.
  • Merck & Co.,Inc.
  • Sanofi
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.

The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Marketed Drugs
  • Route of Administration
  • Drug Type
  • Treatment Channel
  • End User
  • Distribution Channel
  • Region
Breakup by Drug Class
  • Tyrosine Inhibitors
  • MAPK Inhibitors
  • Autotaxin Inhibitors
  • Others
Breakup by Marketed Drugs
  • Ofev
  • Esbriet
  • Pirfenidone
  • Actimmune
  • Nintedanib
  • Interferon Gamma-1b
  • Others
Breakup by Route of Administration
  • Oral
  • Parentals
  • Others
Breakup by Drug Type
  • Over the Counter
  • Prescription
Breakup by Treatment Channel
  • Public
  • Private
Breakup by End User
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Boehringer Ingelheim International GmbH.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Trevi Therapeutics
  • FibroGen,Inc.
  • TORAY INDUSTRIES, INC.
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Asahi Kasei Corporation
  • Galapagos NV
  • ZAMBON COMPANY S.P.A.
  • Novartis AG
  • Neopharm Group
  • Galecto Biotech
  • Kadmon Holding, Inc.
  • Promedior, Inc.
  • Merck & Co.,Inc.
  • Sanofi
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Idiopathic Pulmonary Fibrosis Disease Overview 

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Idiopathic Pulmonary Fibrosis Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
    5.3    Europe Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
    5.4    Asia-Pacific Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
    5.5    Latin America Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
    5.6    Middle East & Africa Idiopathic Pulmonary Fibrosis Epidemiology (2016-2031)
6    Global Idiopathic Pulmonary Fibrosis Treatment Market Overview 
    6.1    Global Idiopathic Pulmonary Fibrosis Treatment Market Historical Value (2017-2023) 
    6.2    Global Idiopathic Pulmonary Fibrosis Treatment Market Forecast Value (2024-2032)
7    Global Idiopathic Pulmonary Fibrosis Treatment Market Landscape
    7.1    Idiopathic Pulmonary Fibrosis Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Idiopathic Pulmonary Fibrosis Treatment: Product Landscape
        7.2.1    Analysis by Drug Class
        7.2.2    Analysis by Marketed Drugs
        7.2.3    Analysis by Route of Administration
        7.2.4    Analysis by Drug Type
        7.2.5    Analysis by End User
8    Idiopathic Pulmonary Fibrosis Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Idiopathic Pulmonary Fibrosis Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Idiopathic Pulmonary Fibrosis Treatment Market Segmentation
    11.1    Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Class
        11.1.1    Market Overview
        11.1.2    Tyrosine Inhibitors
        11.1.3    MAPK Inhibitors
        11.1.4    Autotaxin Inhibitors
        11.1.5    Others
    11.2    Global Idiopathic Pulmonary Fibrosis Treatment Market by Marketed Drugs
        11.2.1    Market Overview
        11.2.2    Ofev
        11.2.3    Esbriet
        11.2.4    Pirfenidone
        11.2.5    Actimmune
        11.2.6    Nintedanib
        11.2.7    Interferon Gamma-1b
        11.2.8    Others
    11.3    Global Idiopathic Pulmonary Fibrosis Treatment Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
            11.3.2.1    Tablets
            11.3.2.2    Capsules
        11.3.3    Parentals
            11.3.3.1    Intravenous
            11.3.3.2    Intramuscular
        11.3.4    Others
    11.4    Global Idiopathic Pulmonary Fibrosis Treatment Market by Drug Type
        11.4.1    Market Overview
        11.4.2    Over the Counter
        11.4.3    Prescription
            11.4.3.1    Branded
            11.4.3.2    Generics
    11.5    Global Idiopathic Pulmonary Fibrosis Treatment Market by Treatment Channel
        11.5.1    Market Overview
        11.5.2    Public
        11.5.3    Private
    11.6    Global Idiopathic Pulmonary Fibrosis Treatment Market by End User
        11.6.1    Market Overview
        11.6.2    Hospitals
        11.6.3    Specialty Clinics
        11.6.4    Homecare Settings
        11.6.5    Others
    11.7    Global Idiopathic Pulmonary Fibrosis Treatment Market by Distribution Channel
        11.7.1    Market Overview
        11.7.2    Hospital Pharmacy
        11.7.3    Retail Pharmacy
        11.7.4    Online Pharmacy
        11.7.5    Others
    11.8    Global Idiopathic Pulmonary Fibrosis Treatment Market by Region
        11.8.1    Market Overview
        11.8.2    North America
        11.8.3    Europe 
        11.8.4    Asia Pacific
        11.8.5    Latin America
        11.8.6    Middle East and Africa
12    North America Idiopathic Pulmonary Fibrosis Treatment Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Idiopathic Pulmonary Fibrosis Treatment Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Idiopathic Pulmonary Fibrosis Treatment Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Idiopathic Pulmonary Fibrosis Treatment Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Idiopathic Pulmonary Fibrosis Treatment Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Boehringer Ingelheim International GmbH.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    AstraZeneca
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    F. Hoffmann-La Roche Ltd.
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Trevi Therapeutics
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    FibroGen,Inc.
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    TORAY INDUSTRIES, INC.
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Pfizer Inc.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Johnson & Johnson Services, Inc.
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Asahi Kasei Corporation
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Galapagos NV
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    ZAMBON COMPANY S.P.A.
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Novartis AG
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Neopharm Group
        23.13.1    Financial Analysis
        23.13.2    Product Portfolio
        23.13.3    Demographic Reach and Achievements
        23.13.4    Mergers and Acquisitions
        23.13.5    Certifications
    23.14    Galecto Biotech
        23.14.1    Financial Analysis
        23.14.2    Product Portfolio
        23.14.3    Demographic Reach and Achievements
        23.14.4    Mergers and Acquisitions
        23.14.5    Certifications
    23.15    Kadmon Holding, Inc.
        23.15.1    Financial Analysis
        23.15.2    Product Portfolio
        23.15.3    Demographic Reach and Achievements
        23.15.4    Mergers and Acquisitions
        23.15.5    Certifications
    23.16    Promedior, Inc.
        23.16.1    Financial Analysis
        23.16.2    Product Portfolio
        23.16.3    Demographic Reach and Achievements
        23.16.4    Mergers and Acquisitions
        23.16.5    Certifications
    23.17    Merck & Co.,Inc.
        23.17.1    Financial Analysis
        23.17.2    Product Portfolio
        23.17.3    Demographic Reach and Achievements
        23.17.4    Mergers and Acquisitions
        23.17.5    Certifications
    23.18     Sanofi
        23.18.1    Financial Analysis
        23.18.2    Product Portfolio
        23.18.3    Demographic Reach and Achievements
        23.18.4    Mergers and Acquisitions
        23.18.5    Certifications
    23.19    Bristol-Myers Squibb Company
        23.19.1    Financial Analysis
        23.19.2    Product Portfolio
        23.19.3    Demographic Reach and Achievements
        23.19.4    Mergers and Acquisitions
        23.19.5    Certifications
    23.20    GlaxoSmithKline plc.
        23.20.1    Financial Analysis
        23.20.2    Product Portfolio
        23.20.3    Demographic Reach and Achievements
        23.20.4    Mergers and Acquisitions
        23.20.5    Certifications
24    Idiopathic Pulmonary Fibrosis Treatment Market- Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market for idiopathic pulmonary fibrosis treatment reached a value of USD 3.59 billion.

The market is anticipated to grow at a CAGR of 5.8% during the forecast period of 2024-2032 to reach a value of USD 5.96 billion by 2032.

The major drivers of the market include the growing prevalence of lung conditions, increasing geriatric population, and rising patient awareness which is likely to propel the demand for idiopathic pulmonary fibrosis treatment.

The increasing number of smokers, which is leading to a rise in prevalence of IPF (idiopathic pulmonary fibrosis) and pollution-triggered lung conditions are expected to be key trends guiding the growth of the market.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Pirfenidone and nintedanib are the different drug-classes in the global idiopathic pulmonary fibrosis treatment market.

The major players in the market are Boehringer Ingelheim International GmbH., Merck & Co., Inc., Cipla Inc., and F. Hoffmann-La Roche Ag, among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER